Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

BACKGROUND: RAS/RAF/MAPK activation is common in myeloid malignancies. Trametinib, a MEK1/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias. METHODS: This pha...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Borthakur, Gautam, Popplewell, Leslie, Boyiadzis, Michael, Foran, James, Platzbecker, Uwe, Vey, Norbert, Walter, Roland B., Olin, Rebecca, Raza, Azra, Giagounidis, Aristoteles, Al-Kali, Aref, Jabbour, Elias, Kadia, Tapan, Garcia-Manero, Guillermo, Bauman, John W., Wu, Yuehui, Liu, Yuan, Schramek, Dan, Cox, Donna S., Wissel, Paul, Kantarjian, Hagop
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5779863/
https://ncbi.nlm.nih.gov/pubmed/26990290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29986
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller